January 13, 2026 5:40pm

Volatility rules …

Consumer price index report showed that core CPI, excluding food and energy rose 0.2% and 2.6% for year. The monthly figure for headline inflation increased 0.3% in December, putting the annual rate at 2.7%.

Pre-open Indications: 4 Hits and 1 Miss

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Tuesday’s RMi Pre-opening: Day #2, JP Morgan healthcare Conference … https://www.regmedinvestors.com/articles/14265

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP! … https://www.regmedinvestors.com/articles/14249

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is pumping the volume and share pricing? … https://www.regmedinvestors.com/articles/13812       

 

The Strange Case of Dr. Jekyll and Mr. Hyde might make for a great read, but it’s far less fun when markets and the C&GT sector act like it’s … been their blueprint

Tuesday: The Dow closed DOWN -398.21 points or -0.80%, the S&P closed DOWN -13.53 points or -0.19% while the Nasdaq closed DOWN -24.032 points or -0.10%

  • Theme of the session: grappling with volatility

Tuesday’s (my) 40-company covered sector’s advance/decline line opened negative with 12 incliners, 25 decliners and 3 flats ending with a neutral close of 19 incliners, 19 decliners and 2 flats

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • Core CPI — excluding food and energy — rose 0.2% on the month and 3% for year.

The CBOE Fear (VIX) index, Tuesday closed at 15.98, after Monday’s 15.09, Friday’s 14.48, Thursday’s 15.47, Wednesday’s 15.34 and last Tuesday’s 14.77

Metrics: Tuesday …

  • The RUT was down -2.59 points or -0.10%,
  • The XLV was down -0.64 points or -0.41%,
  • The NBI was up +0.87 points or +0.02%;
  • The XBI was down -0.08 points or -0.06%
  • The IWM was down -0.15 or -0.06%;
  • The IBB was down -0.08 points or -0.05%,
  • The VIX was up +0.86 points or +5.69% at to 15.98

 

Q1/26 – 1 holiday, 2 neutral, 3 negative and 3 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 19) 

  • Moderna (MRNA +$5.76 after Monday’s -$0.46 after Friday’s +$0.44),
  • BioNTech (BNTX +$5.01 after Monday’s +$2.33 after Friday’s +$1.00),
  • Lenz Therapeutics (LENZ +$1.03),
  • CRISPR Therapeutics (CRSP +$0.88 after Monday’s +$1.46 after Friday’s -$2.56),
  • Beam Therapeutics (BEAM +$0.86 after Monday’s +$6.14),
  • IQIA Holdings (IQV +$0.71 after Monday’s -$1.55 after Friday’s -$0.75),
  • Entrada Therapeutics (TRDA +$0.51),
  • Vericel (VCEL +$0.46 after Monday’s -$1.97 after Friday’s -$2.17),
  • Compass Therapeutics (CMPX +$0.37),
  • Agenus (AGEN +$0.36),

Flat (2)

  • Adverum Biotechnologies ADVM) – acquired
  • Brainstorm Cell therapeutics (BCLI)

Tuesday’s Closing DOWN (10 of 19): 

  • Vertex (VRTX -$5.92 after Monday’s -$3.27 after Friday’s -$5.82),
  • Ionis Pharmaceuticals (IONS -$2.18 after Monday’s +$1.36 after Friday’s -$1.24),
  • uniQure NV (QURE -$1.54 after Monday’s -$2.28 after Friday’s +$2.17),
  • Alnylam Pharmaceuticals (ALNY -$0.95 after Monday’s -$27.38 after Friday’s -$1.11),
  • Mesoblast (MESO -$0.91 after Monday’s -$2.29 after Friday’s +$1.09),
  • AxoGen (AXGN -$0.62 after Monday’s -$1.96 after Friday’s +$0.14),
  • Arrowhead Pharmaceuticals (ARWR -$0.39 after Monday’s +$1.37),
  • Harvard Apparatus RT (OTCQB: HRGN -$0.38 after Monday’s +$0.01 after Thursday’s $0.00)
  • Ultragenyx Pharmaceuticals (RARE -$0.26 after Monday’s +$1.86 after Friday’s -$0.70),
  • BioLife Solutions (BLFS -$0.14 after Monday’s -$0.82),

 

The Bottom Line: More of the … WHY

The Dow led a market retreat from highs with the S&P and Nasdaq followed after the start to earnings season kickoff flopped.

  • The consumer price index reading for December, released Tuesday morning, sparked an early rally, but the gains didn't last very long after the market opened. The headline CPI rose at 2.7% annual rate, which matched expectations. The core CPI, which excludes volatile food and energy prices, came in a touch below expectations at 2.6%. <Barrons>

This new subclade K … flu S c s!  I just is NOT quite over! And I got ALL the SHOTS

 

For all my … <some say> … RANTINGS, I say TRUTH …

Capricor Therapeutics (CAPR) closed Tuesday +$0.28 (having opened -$0.26) after Monday closed up +$0.67 after being DOWN Friday -$1.71 or -6.69% to $23.84 after Thursday’s -$0.76 or -2.89% to $25.55 after Wednesday’s +$0.20 …

  • CAPR’s I-Banks seemed to be executing the “PUMP” to protect the offering share pricing – LOT of daily volume, institution driven … DON’T be distracted – Make a buck, CONTINUE the SELL of the overbought.
  • Right again after again and yet another again … downward!

 

Analysis and follow-up works: Harvard Apparatus RT (OTCQB: HRGN -$0.38 after Monday’s +$0.01 after Friday’s $0.00) after writing this a.m.  

  • As I wrote…
  • Financing on Deck: Harvard Apparatus RT (OTCQB: HRGN (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity” – broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands – partners and employees past and present.
  • An adjunct, who has the lipstick for this pig!

 

Moderna’s (MRNA) equity, depressed for so long, is breaking out—and the gains could keep coming. MRNA dived to a bottom in 2025, and the stock is now putting its foot on the accelerator in 2026.

  • Traded, today at +$5.76 or +17.02 to $39.60  

 

The recent profit-taking could also foreshadow some of the volatility ahead and …

  • RISK is always a factor remaining and … will boil-up under the surface until or as slight shocks rock the C&GT sector and markets!

As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

  • I would be following share pricing’s ascension on current biotech, cell and gene therapy sector upsides; so, some profiteering can be “situated” while maintaining a position, less elevated!

 

January – 3nd week:

  • 1/13 – Tuesday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 1/12 – Monday closed neutral with 19 incliners, 19 decliners and 2 flats

January 2nd week

  • 1/9 - Friday closed negative with 10 incliners, 28 decliners and 2 flats
  • 1/8 – Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 1/7 – Wednesday closed positive with 33 incliners, 4 decliners and 2 flats
  • 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

January’s 1st week:

  • 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
  • 1/1 -Thursday was a holiday, New Years Day

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: Moderna (MRNA), BioNTech (BNTX) and Lenz Therapeutics (LENZ)
  • Monday: Beam Therapeutics (BEAM), BioNTech BNTX) and Ultragenyx Pharmaceuticals (RARE
  • Friday: uniQure NV (QURE), Mesoblast (MESO) and BioNTech (BNTX)
  • Thursday: Mesoblast (MESO), AxoGen (AXGN) and Intellia Therapeutics (NTLA)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and IQVIA Holdings (IQV),
  • Last Tuesday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)

The worst three (3) in the session: Losers

  • Tuesday: Vertex (VRTX), Ionis Therapeutics (IONS) and uniQure NV (QURE)
  • Monday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Sarepta Therapeutics (SRPT)
  • Friday: Vertex (VRTX), CRISPR Therapeutics CRSP) and Vericel (VCEL)
  • Thursday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Moderna (MRNA)
  • Wednesday: Arrowhead Pharmaceuticals (ARWR), BioLife Solutions (BLFS) and LENZ Therapeutics (LENZ)
  • Last Tuesday: AxoGen (AXGN), Ultragenyx Pharmaceuticals (RARE) and Entrada Therapeutics (TRDA)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.